Brought to you by 
Roche, Chugai license Xencor's XmAb to enhance antibodies
29 Sep 2021
Executive Summary
Xencor (engineering antibodies to treat cancer, inflammation, and autoimmune diseases) has licensed Roche and its Japanese affiliate Chugai Pharmaceutical Co. Ltd. individual rights to use its flagship XmAb optimization technology for one year to enhance antibodies against undisclosed cancer targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche, Chugai license Xencor's XmAb to enhance antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice